LancetOncol标准一线化疗单独
2016-12-29 来源：本站原创 浏览次数：次BackgroundAngiogenesisisatargetinthetreatmentofovariancancer.Nintedanib,anoraltripleangiokinaseinhibitorofVEGFreceptor,platelet-derivedgrowthfactorreceptor,andfibroblastgrowthfactorreceptor,hasshownactivityinphase2trialsinthissetting.Weinvestigatedthe北京哪里治疗白癜风较好北京最好白癜风医院电话
健康热线：